Insider Selling: Invivyd, Inc. (NASDAQ:IVVD) Director Sells 86,545 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) Director Terrance Mcguire sold 86,545 shares of the stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $0.48, for a total value of $41,541.60. Following the completion of the transaction, the director now owns 3,170,231 shares in the company, valued at approximately $1,521,710.88. The trade was a 2.66 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Terrance Mcguire also recently made the following trade(s):

• On Thursday, December 26th, Terrance Mcguire sold 83,817 shares of Invivyd stock. The shares were sold at an average price of $0.54, for a total transaction of $45,261.18.
• On Monday, December 23rd, Terrance Mcguire sold 75,776 shares of Invivyd stock. The stock was sold at an average price of $0.45, for a total transaction of $34,099.20.
• On Friday, December 20th, Terrance Mcguire sold 119,805 shares of Invivyd stock. The shares were sold at an average price of $0.42, for a total transaction of $50,318.10.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total value of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total value of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The stock was sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Stock Down 4.0 %

Shares of Invivyd stock traded down $0.02 during trading on Tuesday, reaching $0.44. The company's stock had a trading volume of 1,067,606 shares, compared to its average volume of 671,774. The business has a 50 day moving average price of $0.71 and a 200-day moving average price of $0.95. The company has a market capitalization of $53.00 million, a P/E ratio of -0.23 and a beta of 0.53. Invivyd, Inc. has a 12-month low of $0.40 and a 12-month high of $5.20.

Institutional Investors Weigh In On Invivyd

Several institutional investors have recently made changes to their positions in the stock. Duquesne Family Office LLC acquired a new stake in Invivyd in the second quarter valued at $629,000. Acadian Asset Management LLC grew its stake in Invivyd by 232.0% in the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company's stock valued at $745,000 after acquiring an additional 474,301 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Invivyd during the 2nd quarter valued at about $421,000. Bank of New York Mellon Corp purchased a new position in Invivyd during the 2nd quarter valued at about $263,000. Finally, Dimension Capital Management LLC raised its position in Invivyd by 243.3% during the second quarter. Dimension Capital Management LLC now owns 189,871 shares of the company's stock worth $209,000 after acquiring an additional 134,571 shares during the last quarter. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on IVVD shares. Morgan Stanley dropped their price objective on shares of Invivyd from $9.50 to $3.55 and set an "overweight" rating on the stock in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded Invivyd to a "strong-buy" rating in a research report on Wednesday, October 30th. D. Boral Capital reaffirmed a "buy" rating and set a $9.00 price objective on shares of Invivyd in a research report on Thursday, November 21st. Finally, HC Wainwright dropped their target price on Invivyd from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, November 20th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $7.89.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.